Complement 3 Glomerulopathy (C3G)
Complement 3 Glomerulopathy, or C3G, is a rare kidney disease in which a protein called C3 gets deposited into the filtering units of the kidney. These deposits disrupt kidney function and cause progressive damage to the filtering units called glomeruli.
Rarediseases.org/c3g
Common symptoms of C3G include blood in the urine, dark or foamy urine which could mean protein in the urine, swelling or edema, high blood pressure, and decreased urine output.
C3G can only be diagnosed by a kidney biopsy. Urine and blood tests can help support the diagnosis after a biopsy.
Fabhalta (iptacopan)
Empaveli (pegcetacoplan)
FABHALTA (IPTACOPAN)
Fabhalta (iptacopan) is a complement factor B inhibitor, indicated for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria. Fabhalta.com/c3g
EMPAVELI (PEGCETACOPLAN)
Empaveli (pegcetacoplan) is a complement inhibitor, indicated for the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), to reduce proteinuria. Empaveli.com/c3g
Patient Resources
National Organization for Rare Disorders (NORD) supports patient advocacy, education, and research.
The National Kidney Foundation is a voluntary, non-profit organization dedicated to preventing kidney and urinary tract diseases, improving the health and well-being of individuals and families affected by these diseases, and increasing the availability of organs for transplantation.
